NANETS2024 17th Annual Multidisciplinary NET Medical Symposium NANETS 2024 Applied Basic Science (13 abstracts)
1Department of Medicine, Division of Medical Oncology, University Hospitals, Seidman Cancer Center, Case Western Reserve University, Cleveland, OH; 2Tempus AI, Inc., Chicago, IL; 3Department of Pathology, University Hospitals, Seidman Cancer Center, Case Western Reserve University, Cleveland, OH; 4Department of Radiology, University Hospitals, Seidman Cancer Center, Case Western Reserve University, Cleveland, OH; 5Department of Surgical Oncology, University Hospitals, Seidman Cancer Center, Case Western Reserve University, Cleveland, OH; 6Department of Radiation Oncology, University Hospitals, Seidman Cancer Center, Case Western Reserve University, Cleveland, OH
Background: Extra-pulmonary neuroendocrine carcinomas (EP-NECs) are rare and aggressive cancers that include two morphological subtypes: large cell NEC (LC-NEC) and small cell NEC (SC-NEC). Although they are treated with similar chemotherapy regimens, they are distinct diseases, and their genomic profiles have not been compared. We investigated the genomic profile of the extrapulmonary LC-NEC and SC-NEC to identify mutations that could enable more personalized therapy.
Methods: Patients diagnosed with poorly differentiated extra-pulmonary NECs (LC-NEC and SC-NEC subtypes) were selected from the de-identified Tempus real-world multimodal database. Patient demographic/clinical characteristics and genomic/transcriptomic data were described as N (%) or median (IQR), min, and max and compared between subgroups by Chi-squared/Fishers Exact tests or Wilcoxon rank-sum tests, as applicable. The prevalence of somatic mutations (SNVs, CNVs, and Fusions) was described and compared similarly, with a false-discovery rate correction for multiple comparisons. Analyses were two-sided, with statistical significance evaluated at the 0.05 alpha level.
Results: 307 patient samples (121 LC-NECs and 186 SC-NECs) were identified. There was no difference in race and ethnicity between LC and SC NECs. There were no significant differences in median TMB between LC and SC-NECs (3.1 vs 3.4 mut/Mb, P = 0.2, respectively); the majority had low TMB (<10 mut/Mb). LC-NECs had higher frequency of deletions vs SC-NECs in CDKN2A (12% vs 1.6%, q=0.002), CDKN2B (12% vs 1.6%, q=0.002), and MTAP (9.9% vs 1.1%, q=0.002). SC-NECs had more frequent RB1 loss compared to LC-NECs, although not significant after correction for multiple testing (16% vs 7.4%, q=0.2). LC-NECs have more common CCND1, FGF3, FGF4, KDM5A, NOTCH1, and MYC amplifications, but less common SDHC, SLAMF1, FCGR2A, FCGR3A, and NIT1 amplifications compared to SC-NECs. SNVs in APC, KRAS, BRAF, DAXX, NOTCH1, and SMARCA4 mutations were more common in LC-NECs, while RB1, TERT, and FOXA1 mutations were more common in SC-NECs.
Conclusions: Our results demonstrated that EP-NECs display a broad pattern of genomic alterations according to their histological subtypes. These distinct molecular signatures could impact the development of future precision therapeutics for SC-NECs and LC-NECs.
ABSTRACT ID28479